NICE Diagnostics Advisory Committee members

Professor Adrian Newland CBE

Professor Newland has been a Consultant Haematologist at Barts and the London NHS Trust for almost 30 years, and Professor of Haematology at Queen Mary's School of Medicine and Dentistry (Barts and the London), since 1995. He is Director of Pathology for the Trust. He took up the position as Chair having already held a number of high-profile positions, including President of the Royal College of Pathologists (2005 - 2008), and Director of the North East Thames Cancer Network (2001 - 2013), amongst many others. He is currently chair of the Healthcare Forum of the UK Accreditation Service, Pathology Diagnostic Advisor to NHS England (London) and also Vice-Chair of the national Chemotherapy Clinical Reference. Professor Newland also chaired the London Cancer New Drugs Group, which has a remit to review drugs that have not yet been through the NICE assessment process and currently runs the Cancer Drug Fund in London.

Professor Ron Akehurst
Professor Emeritus in Health Economics, School of Health and Related Research (ScHARR) at the University of Sheffield

Ron Akehurst is Professor Emeritus in Health Economics, a major centre for Health Services Research in Europe with some 300 staff. ScHARR is a major supplier of analytical services to NICE, including assessment reports, evidence reviews, and decision support for the development of clinical guidelines and Interventional Procedures guidance.

His interests are primarily in Health Technology Assessment (HTA) and he has published widely in that area. He has had some involvement in developing HTA processes in other countries, including Hungary and Korea. Ron was a founding member of the National Institute for Clinical Excellence (NICE) Appraisal Committee, serving on it for 7 years; and has also served on the NICE Topic Selection Committee and the NICE Public Health Interventions Advisory Committee. He is a current member of NICE Highly Specialised Technologies Committee and NHS England Rare Diseases Advisory Group.

Past activities include a 2 year period as an Economic Advisor to the Department of Health and as a Specialist Advisor to the Parliamentary House of Commons Health Select Committee for 3 years. Ron spent 3 years as a Non-Executive Director of a Health Authority, responsible for commissioning Health Services.

Dr Paul Collinson MA, MB, BChir, FRCPath, MD
Consultant Chemical Pathologist to St George's Hospital

Paul Collinson's clinical interests are in the management of Cardiovascular Risk and Research interest in the pathogenesis, diagnosis and management of acute coronary syndromes.

He has a special interest the cost economics of cardiac care, point of care testing and evidence based laboratory medicine and is clinical lead for the National Laboratory Medicine Catalogue.

Dr Sue Crawford MRCP MRCGP DipRCPath
General Practitioner in Devon

Dr Sue Crawford is a general practitioner with an interest in diagnostics and in improving the primary / secondary care working interface.

She has been a partner in a rural dispensing practice in the South Hams for the last 3 years.

During this time she has established the practice as part of the Primary Care Research Network. For 10 years prior to moving to Devon she combined roles as an Associate Specialist in Haematology in West Dorset with being an assistant to a single handed rural GP and GP educator for the Dorset GP training scheme. She now represents the practice on the local commissioning consortium.

Professor Ian Cree
Yvonne Carter Professor of Pathology, University of Warwick

Ian Cree trained as a general pathologist and has a PhD in immunology. He has held posts as a consultant pathologist in Dundee, in London at the Institute of Ophthalmology, and in Portsmouth, where he was Professor of Histopathology at the University of Portsmouth and Director of the Translational Oncology Research Centre. He also chairs the Inter-speciality Committee on Molecular Pathology for the Royal College of Pathologists and sits on the NICE Diagnostics Advisory Committee. He was previously Director of the Efficacy and Mechanism Evaluation (EME) programme for the UK National Institute of Health Research Evaluation Trials and Studies Coordinating Centre (2008 -2012). Ian is a member of grants boards for the NIHR and Wellcome Trust, and a section editor for BMC Cancer. Trained as a general pathologist with a PhD in immunology, Ian's research career has been based on investigating disease mechanisms to improve diagnosis and treatment. This has involved him designing, conducting and leading clinical trials as well as a number of large multicentre studies. Ian's current research interests are mostly cancer-related, but previous studies have included infectious disease, asthma, and ophthalmology. He has published over 200 papers, and two books. For the last 20 years, Ian has been involved in developing predictive methods to allow individualised therapy of cancer. He has recently been involved in the implementation within pathology departments of mutation testing services, including external quality assurance schemes. Since coming to Warwick, Ian has developed a nationally based Early Cancer Detection Consortium.

Professor Erika Denton FRCP, FRCR
National Clinical Director for Diagnostics, NHS England

Erika was appointed to the role of National Clinical Director for Diagnostics in spring 2013. From 2005-2013 Erika was National Clinical Lead, and subsequently National Clinical Director, for Imaging at DH leading a complex programme of work across all aspects of imaging. This work delivered considerable additional capacity for imaging services and marked reduction in waiting times. Her work has included delivering significant improvements in Cancer, Paediatric, Interventional, Cardiac and Forensic imaging services. In her roles in Connecting for Health she has led deployment of PACS systems across the NHS and is now leading the process to move PACS to local NHS ownership.

Erika was previously Divisional Clinical Director for support services, Director of Breast Screening and head of radiology training in Norwich. She continues to practice clinically 2 days a week and to publish in breast imaging and health care policy.

Mr David Evans
Lay member, Safety Engineer and Occupational Hygienist

Previously worked in the Electricity Supply Industry in the same disciplines and earlier as an Electrical Engineer in the design, construction and operation of high voltage electricity distribution systems in England and Wales.

Is/has been involved as a Lay Member with Medical Royal Colleges/Societies, NICE, PMETB/GMC, JRCPTB, SHAs, CHI/Healthcare Commission, National Hospital for Neurology and Neuroscience and Great Ormond Street Hospital. He is a Referee, College of Experts, NHIR HTAP, Southampton University, a member of the HSC ‘Safety of Work Equipment' Working Group and Examinations Invigilator and Amanuensis for students with disabilities, Open University.

Member of Professional Interview Panels, Institution of Occupational Safety and Health and also the Engineers and Managers Association National Safety, Health and Environment Committee.

Dr Steve Edwards BSc (Hons) MSc DPhil
Head of Clinical and Economic Evidence, BMJ-TAG, BMJ

For more than 15 years Steve has conducted systematic reviews and health economic evaluations in a range of therapeutic areas including cardiovascular, CNS, gastroenterology, infection, oncology, and respiratory medicine. He currently leads a technology assessment group, based at the BMJ, which supports the NICE Technology Appraisal Programme.

He is also an Honorary Lecturer in Public Health at the London School of Hygiene and Tropical Medicine, a member of the Cochrane Pregnancy & Childbirth Group, and the statistics advisor for diagnostic test accuracy systematic reviews for the Cochrane Skin Group.

Dr Simon Fleming MSc, MD, FRCPath
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Cornwall Hospital.

Simon Fleming is a Consultant in Clinical Biochemistry and Metabolic Medicine in Cornwall and Honorary Teacher at the Peninsula College of Medicine and Dentistry. He trained in London and Newcastle upon Tyne and has specialist interests in lipidology, diabetes, clinical nutrition and cardiovascular research.

He has previously worked as a reviewer for National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the HTA Diagnostics Programme.

Professor Chris Hyde
Professor of Public Health & Clinical Epidemiology, Peninsula College of Medicine and Dentistry

Chris Hyde trained in medicine and public health in London and East Anglia respectively. His expertise is in systematic reviews and health technology assessments, particularly in the context of providing support to policy-makers. In this respect he has undertaken many reports for NICE, particularly its Technology Appraisal Programme.

During his career he has set up and directed the Aggressive Research Intelligence Facility (ARIF), an effectiveness information support service for commissioners in the West Midlands. Chris has also directed the West Midlands Health Technology Assessment Collaboration and been closely involved with the Systematic Reviews Initiative of the National Blood Service. He has long-standing connections with the Cochrane Collaboration and is an editor of the NHS HTA Monograph series. He is currently based at the Peninsula College of Medicine and Dentistry where he leads the Technology Appraisal Group in PenTAG.

He has a long-standing interest in the evaluation of tests and has done health technology assessments on many topics including automated cervical screening, hysteroscopy, prediction of pre-eclampsia and pre-term birth, PET/CT, orthopantomography and identifying genetic sub-types in diabetes. He is currently part of the UK Support Unit for Cochrane Diagnostic Test Accuracy Reviews based at the University of Birmingham; and a member of the Cochrane Diagnostics Test Accuracy Editorial Board.

Dr Mark Kroese MB ChB, DPH, FFPH, FRCP(Ed), MRCGP
Consultant in Public Health Medicine, PHG Foundation, Cambridge and UK Genetic Testing Network

Mark Kroese is a Consultant in Public Health Medicine at the PHG Foundation, Cambridge and was appointed Public Health Advisor to the UK Genetic Testing Network in 2006. Prior to joining the PHG Foundation, Mark worked for nearly 7 years as Consultant in Public Health Medicine at Peterborough Primary Care Trust.

His specialist interests are in the evaluation and regulation of genetic tests and the commissioning of clinical genetics services.

Mr Mathew Lowry
Director of Finance & Infrastructure, Doncaster and Bassetlaw Hospitals NHS FT

Matthew Lowry has a background in NHS finance and operational management, holding Director level positions in both commissioning and provider organisations for the last 12 years. He is currently the Director of Finance and Infrastructure for Doncaster and Bassetlaw Hospitals NHS FT, a large acute Trust employing c.6,000 staff.

He has a first degree in Economics and is a CIMA qualified accountant. He has a particular interest in operating theatre productivity, supporting the NHS Institute's work in this area.

Dr Michael Messenger
Deputy Director and Scientific Manager - NIHR Diagnostic Evidence Co-operative Leeds

Dr Michael Messenger is the Deputy Director and Scientific Manager for the NIHR Diagnostic Evidence Co-Operative Leeds and is responsible for overseeing the delivery of high quality scientific evidence on in-vitro diagnostics (IVD) for the NHS. As the Principal Healthcare Scientist on a NIHR Applied Programme Grant for Research “Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease” he has experience across many phases of the “diagnostic pipeline” including the development, validation and clinical evaluation of new diagnostic assays.

Dr Peter Naylor
General Practitioner, Chair Wirral Health Commissioning Consortia

Dr Pete Naylor is a General Practitioner in Wallasey, Wirral where he has been for 14 years. Over many of these years he has been involved in healthcare management and is now Assistant Clinical Chair to Wirral Clinical Commissioning Group and Chair of Wirral Health Commissioning Consortium. He has particular interests in integrated working, quality, engagement and the appropriate development of telehealth technologies. He admits to a core drive to the reduction of health inequalities and this is a problem he particularly faces in his local area.

Mr Dermot Neely
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle Upon Tyne.

Dermot Neely is a Consultant in Clinical Biochemistry and Metabolic Medicine in Newcastle Upon Tyne Hospitals NHS Trust and Associate Clinical Lecturer at the University of Newcastle. He trained in Belfast and has specialist interests in lipidology and cardiovascular research. He is Director of the Newcastle Supra-Regional Assay Service (SAS) Cardiovascular Biomarkers and Endocrine Laboratories and is Lead for Evaluation for the Newcastle NIHR Diagnostic Evidence Co-operative.

He has previously served as a member of the Guideline Development Group for the NICE Lipid Modification Guideline (CG67) Review and as a reviewer for the HTA Diagnostics Programme.

Dr Richard Nicholas
Consultant Neurologist at Heatherwood and Wexham Park Hospital, Imperial Healthcare Trust.

Richard Nicholas is a Consultant Neurologist at Heatherwood and Wexham Park Hospital, Imperial Healthcare Trust and is an Honorary Senior Lecturer at Imperial College.

He specialises in Multiple Sclerosis running a NHS disease modifying therapy clinic and helping to set up the NHS natalumizab infusion service at Imperial, currently the largest in the UK. He is a Trustee of the Multiple Sclerosis Trials Collaboration a charity aiming to facilitate access to new and emerging therapies for people with MS and he is clinical director of the UK Multiple Sclerosis Tissue Bank.

He is involved in pharmaceutical and academic clinical trials as well as basic science projects aiming to develop novel approaches to treatments, new trial designs and new methods of disease evaluation in Multiple Sclerosis.

Mrs Gail Norbury MA MSc FRCPath
Consultant Clinical Scientist, Genetics Centre, Guy's & St Thomas' NHS Foundation Trust

Gail Norbury is the Commissioning and Governance Director for the Laboratories of the Regional Genetics Service at Guy's & St Thomas' Hospital. She has 30 years' experience as Clinical Scientist and has a wealth of experience in the development and delivery of diagnostic laboratory services in the NHS. Gail's professional roles include being Chair of Royal College of Pathologists Special Advisory Committee for Genetics & Reproductive Science and National Laboratory Medicine Catalogue Specialist Lead for Genetics. Alongside these she serves on a number of committees for the UK Genetic Testing Network (UKGTN), Association of Clinical Genetic Science (ACGS), Academy of Health Care Science (AHCS)and London & the South Clinical Genetics Network Advisory Group. Her main focus is on the delivery of clinically effective and efficient genetic testing services and she has publications spanning a range of disorders and analytical techniques.

Dr Diego Ossa MD, MSc
Global Director of Market Access, Novartis Molecular Diagnostics

Dr Diego Ossa is a Global Director of Market Access at Novartis. His main objective is to develop, drive and execute the Global Market Access strategy for Novartis compounds/brands from proof-of-concept (PoC) to 18 months post launch across the Business Franchise.

Diego is a trained health economist with over 10 years of experience, as well as a medical doctor with specialised training in clinical genetics. Before assuming his current role, Diego held market access and health economic positions at Novartis in Molecular Diagnostics as well as for Global Pharma developments, and in the UK for overall development and implementation of national guidance submission strategies to relevant bodies. Before joining Novartis, Diego worked in health economic consultancy gaining vast expertise in health economic methods.

Diego is a strong believer in personalised medicine. He thinks that molecular diagnostics provides patients with the opportunity to achieve better outcomes through personalised therapies, which can translate into better health-care provision and better value-for-money alternatives.

Professor Mark Sculpher BA (Hons), MSc, PhD
Professor of Health Economics, Centre for Health Economics, University of York

Mark Sculpher has worked in the field of economic evaluation and health technology assessment for over 25 years. He has researched in a range of clinical areas including heart disease and cancer, and evaluated therapeutic and diagnostic technologies He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty. He has over 200 peer-reviewed publications and is a co-author of two major text books in the area.

Mark is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the NICE Technology Appraisal and Public Health Interventions Advisory Committees. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation; and has also advised health systems internationally on HTA methods including those in Ireland, Portugal, France and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme and currently sits on the UK Medical Research Council's Methodology Research Panel.

Dr Steve Thomas MBBS, MRCP, FRCR, MSc
Consultant Vascular and Cardiac Radiologist at Sheffield Teaching Hospitals Foundation Trust.

Steve Thomas is a Consultant Cardiovascular Radiologist with expertise in diagnostic and interventional vascular radiology, and non- invasive assessment of cardiac disease using Cardiac Magnetic Resonance imaging and Computed Tomography. He is an Honorary Clinical Senior Lecturer at the University of Sheffield, where he has been carrying out Health Economic and Technology Appraisal research into new techniques/ technologies and diagnostics relevant to his clinical work.

Mr Paul Weinberger
Chief Executive, Diasolve Ltd

Paul is Chief Executive of Diasolve, founded in 2010 to help inventors and companies bring innovative, cost-effective diagnostic products to market. He has worked in the pharmaceutical, medical devices and diagnostics industries for nearly twenty five years. Paul is a member of the Executive Committee and former Chairman of the UK diagnostics trade association, BIVDA. He has also served as a consultant to the Technology Strategy Board and is now a member of the Stratified Medicine Catapult advisory board. He holds a first degree in pharmacology and an MBA from London Business School.

This page was last updated: 17 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.